Effect of berberine on PPARα/δ/γ expression in type 2 diabetic rat retinae

Yaoxue Xuebao

Volumn 42, Issue 12, 2007, Pages 1243-1249

  Zhou, Ji yin ^a   Zhou, Shi wen ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Berberine; Diabetic retinopathy; Immunohistochemistry; Peroxisome proliferator activated receptor

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; BERBERINE; FENOFIBRATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE;

ANIMAL; ARTICLE; DIABETIC RETINOPATHY; EXPERIMENTAL DIABETES MELLITUS; MALE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; RAT; RETINA; WISTAR RAT;

ANIMALS; BERBERINE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; HYPOGLYCEMIC AGENTS; MALE; PPAR ALPHA; PPAR DELTA; PPAR GAMMA; PROCETOFEN; RATS; RATS, WISTAR; RETINA; THIAZOLIDINEDIONES;

EID: 38949106586     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Javitt JC, Canner JK, Frank RG, et al. Detecting and treating retinopathy in patients with type I diabetes mellitus. A health policy model [J]. Ophthalmology, 1990, 97:483-494.
2. Antonetti DA, Barber AJ, Bronson SK, et al. Diabetic retinopathy [J]. Diabetes, 2006,55:2401-2411.
3. Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents: an update [J]. Drug Saf, 2005,28:601-631.
4. Wierzbicki - AS. FIELDS of dreams, fields of tears: a perspective on the fibrate trials [J]. Int J Clin Pract, 2006,60:442-449.
5. Li WL, Zheng HC, Bukuru J, et al. Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus [J]. J Ethnopharmacol, 2004,92: 1-21.
6. Sun M, Fan HW, Ma HY, et al. Protective effect of total glucosides of Picrorhiza scrophulariiflora against oxidative stress in glomerular mesangial cells induced by high glucose [J]. Acta Pharm Sin, 2007,42: 381-385.
7. Leng SH , Lu FE, Xu LJ. Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion [J]. Acta Pharmacol Sin, 2004, 25: 496-502.
8. Berger JP, Akiyama TE, Meinke PT. PPARs: therapeutic targets for metabolic disease [J]. Trends Pharmacol Sci, 2005,26:244-251.
9. Tang LQ, Wei W, Chen LM, et al. Effects of berberine on diabetes induced by alloxan and a high-fat/high-cholesterol diet in rats [J]. J Ethnopharmacol, 2006, 108:109-115.
10. Srinivasan K, Viswanad B, Asrat L, et al. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening [J]. Pharmacol Res, 2005,52:313-320.
11. Zhao MM, Li Z, Teng Z, et al. Repeated oral treatment with polysaccharide sulfate reduces insulin resistance and dyslipidemia in diabetic dyslipidemic rat model [J]. Acta Pharm Sin, 2007, 42:488-491.
12. Israelian-Konaraki Z, Reaven PD. Peroxisome proliferator-activated receptor-alpha and atherosclerosis: from basic mechanisms to clinical implications [J]. Cardiol Rev, 2005,13:240-246.
13. Luquet S, Gaudel C, Holst D, et al. Roles of PPAR delta in lipid absorption and metabolism: a new target for the treatment of type 2 diabetes [J]. Biochim Biophys Acta, 2005,1740:313-317.
14. Zeng QL, Wang HQ, Luo H, et al. Synthesis of phenyloxyisobutyric acid derivatives and their antidiabetic activity in vitro [J]. Acta Pharm Sin, 2006,41:108-114.
15. Tang L, Yang YS, Ji RY. Design, synthesis and insulin-sensitizing activity of indole derivatives [J]. Acta Pharm Sin, 2006,41:225-229.
16. Engerman RL, Kern TS. Retinopathy in animal models of diabetes [J]. Diabetes Metab Rev, 1995,11:109-120.
17. Ishibashi T, Inomata H. Ultrastructure of retinal vessels in diabetic patients [J]. Br J Ophthalmol, 1993,77: 574-578.
18. Park SH, Park JW, Park SJ, et al. Apoptotic death of photoreceptors in the streptozotocin-induced diabetic rat retina [J]. Diabetologia, 2003,46:1260-1268.
19. Bonne C. PPAR gamma: a novel pharmacological target against retinal and choroidal neovascularization [J]. J Fr Ophthalmol, 2005, 28:326-330.
20. Elangbam CS, Tyler RD, Lightfoot RM. Peroxisome proliferator-activated receptors in atherosclerosis and inflammation - an update [J]. Toxicol Pathol, 2001, 29:224-231.
21. Aoun P, Simpkins JW, Agarwal N. Role of PPAR-gamma ligands in neuroprotection against glutamate-induced cytotoxicity in retinal ganglion cells [J]. Invest Ophthalmol Vis Sci, 2003,44:2999-3004.
22. 3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise [J]. Diabetes, 2003, 52: 1926-1934.